Preliminary statistics from VCBeat tracked 23 financing events in China's healthcare sector between Sept. 28-Oct. 11, 2026 (excluding IPOs and private placements). Topping the list is Leadsynbio's RMB 450 million Pre‑IPO round, followed by Kunwei's RMB 400 million financing.

A team led by renowned respiratory specialist Zhong Nanshan and KingMed Diagnostics has unveiled DeepGEM 2.0, a multimodal AI model that predicts 12 lung cancer-related gene mutations directly from routine digital pathology slides in just one minute, aiming to significantly reduce genetic testing costs. In another major breakthrough, Haohai Biotech has received NMPA approval for 'Shiyouning', the world's first retinal hole sealing gel, which treats retinal detachment without requiring patients to maintain a prone position post-surgery. The briefing also covers other key industry updates, including stricter EU oversight on high-risk IVDs, Haier Biotech leading a new international standard for medical cold storage, ZEISS acquiring a holographics firm, and recent FDA clearances for medical devices and AI tools.

Hong Kong's healthcare IPO market weakened sharply in 2026 as listing premiums faded and investor sentiment cooled. In Q3, only two healthcare companies went public, both suffering first-day losses. Highly anticipated listings such as MEDCAPTAIN and Beijing TRT Healthcare also saw steep post-listing declines, with some new listings falling over 60%. The downturn reflects tighter primary-market risk appetite, weaker secondary-market confidence, and reduced tolerance for valuations based on early-stage narratives. IPO activity has consequently slowed, with more companies delaying or abandoning plans. A key factor is the crowded approval pipeline: 87 companies remained in the queue as of September 21, prolonging review cycles and discouraging new applications. The market is entering a phase of more rational restructuring.

Shenzhen Shenyi Technology, founded in May 2025, focuses on "AI + brain science," productizing brain-computer interface (BCI) technology for real-world use. It closed an angel round of over RMB 10 million led by Leaguer Venture Capital. Founder Gu Xiangkun advocates "ask about the scenario first, then choose the technology": as sleep and emotion management need long-term intervention and surgery sees low acceptance, Shenyi chose a non-invasive route to reach more people. Its two-way "acquisition–understanding–intervention" loop captures EEG signals via self-developed modules, analyzes brain states and disease features with AI algorithms, then applies neuromodulation, completing a "perception–understanding–intervention–feedback" cycle. Shenyi is exploring productization in sleep improvement, depression treatment, and deep-brain modulation, addressing the industry's fragmented single-point technologies and scaling brain health technology systematically.

GensKey’s self-developed mNGS kit has received a Class III medical device registration certificate from China’s National Medical Products Administration (NMPA), marking China’s first Class III registration for pathogen metagenomic testing and the first mNGS infectious pathogen diagnostic kit approved by a national regulator worldwide. The U.S. FDA has yet to approve any mNGS diagnostic kit, while the EU has not completed approval of any broad-spectrum infectious pathogen mNGS sequencing kit. China’s lead reflects strong clinical demand and rapid technological iteration. With mNGS and tNGS still at low penetration but high growth, clinical needs are accelerating standardization, regulatory approval and reimbursement. As a key tool for severe and complex infections, mNGS has historically relied on centralized laboratories with limited standardization. The new Class III approval could reshape the market and unlock a billion-yuan incremental opportunity.

Hansoh Pharmaceutical Group Company Limited (HKEX: 03692) has re-submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for aumolertinib, its proprietary third-generation EGFR tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC). The EMA has confirmed acceptance of the application, which has passed the initial validation check and will now proceed to a full scientific review by the Committee for Medicinal Products for Human Use (CHMP). This re-submission marks a significant milestone in Hansoh Pharmaceutical's ongoing efforts to expand its international regulatory footprint and bring aumolertinib to the European market.

Zhejiang Wolwo Biopharmaceutical Co., Ltd. (WOLWOPHARMA) announced on October 11 that its indirectly controlled subsidiary, Zhejiang Wolwo Stem Cell Technology Co., Ltd., has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for its Human Umbilical Cord Mesenchymal Stem Cell Type II Injection. The investigational therapy is indicated for the treatment of sepsis and/or septic shock, life-threatening conditions with high mortality rates and limited therapeutic options globally. The approval marks a significant milestone in WOLWOPHARMA's expansion into regenerative medicine. The mesenchymal stem cell injection has demonstrated immunomodulatory and anti-inflammatory properties in preclinical studies, which could potentially help mitigate the cytokine storm associated with severe sepsis.

On October 10, 2026, China’s National Medical Products Administration approved Coyote Biotech’s Mycobacterium tuberculosis Complex Nucleic Acid Detection Kit, the country’s third tongue swab-based molecular TB test. Compatible with tongue swab and sputum samples, it integrates with the company’s Flash Nano platform to provide China’s first tongue swab-based molecular POCT system for TB. In a multicenter study of 687 suspected TB patients, sputum testing achieved 98.95% sensitivity and 98.69% specificity, while tongue swab testing reached 99.70% sensitivity and 98.32% specificity. Following Hugo Biotech’s launch in December 2025 and Dian Diagnostics’ dual-sample kit in August 2026, the approval intensifies competition in a market addressing the challenge that nearly 40% of suspected TB patients cannot provide qualified sputum samples.

In 2026, Midea Group completed a 100% takeover of Esaote, Europe's largest ultrasound equipment producer, folding it into its Healthcare Division. After Wandong Medical and Carestream, the deal is another heavyweight cross-border move, completing Midea's high-end global positioning. Since taking over Wandong in 2021, Midea has set its imaging strategy, consolidating KUKA and Swisslog via sustained R&D and capital moves, launching an independent Healthcare Division in 2025 as a core group segment. With former GE HealthCare executive Chen Jinlei joining and the deal closed, Midea has built a global sales and qualification network spanning ultrasound, DR, MRI and digital imaging. From loose appliance-adjacent incubation to high-profile industrial M&A, Midea is shaking up the global medical imaging market as a competitor not to be ignored.

Newsoara Biopharma and cAMPfield Therapeutics announced that their selective PDE4B inhibitor prifemilast significantly outperformed Amgen's apremilast (Otezla) in a Phase 3 head-to-head trial for moderate-to-severe plaque psoriasis. Among 607 patients, prifemilast 20 mg once daily achieved a 64.6% PASI 75 response rate at Week 16 versus 35.3% for apremilast 30 mg twice daily, with 55.6% of patients reaching sPGA 0/1 skin clearance compared to 31.3% on apremilast. Safety profiles were broadly comparable between the two arms. Newsoara plans to file a New Drug Application in China by year-end 2026.

In an interview with VCBeat's "Going Global" column, Puyi Bio Deputy General Manager Wei Zheng discusses how device makers go global. As centralized procurement becomes routine for high-value consumables in China, going global is now a must. Focused on high-end implantable and interventional products, Puyi Bio leans on two core in-house technologies—absorbable polymers and sustained drug release—to win multiple registration certificates at home and abroad. Its distinctive strategy is "patents go global first": overseas patent filings and approvals lead, opening U.S. and European registration pathways and letting the global market feed back into China. As a front-runner in bioabsorbable coronary stents, Puyi Bio cites XinSorb, its first proprietary product, to illustrate a "global first, China later" reverse expansion.

In 2026, Midea Group completed a 100% takeover of Esaote, Europe's largest ultrasound equipment producer, folding it into its Healthcare Division. After Wandong Medical and Carestream, the deal is another heavyweight cross-border move, completing Midea's high-end global positioning. Since taking over Wandong in 2021, Midea has set its imaging strategy, consolidating KUKA and Swisslog via sustained R&D and capital moves, launching an independent Healthcare Division in 2025 as a core group segment. With former GE HealthCare executive Chen Jinlei joining and the deal closed, Midea has built a global sales and qualification network spanning ultrasound, DR, MRI and digital imaging. From loose appliance-adjacent incubation to high-profile industrial M&A, Midea is shaking up the global medical imaging market as a competitor not to be ignored.

In August 2026, China's first commercial-scale dual-chamber lyophilized formulation production line completed equipment installation at WuXi Biologics' Chengdu facility. Initiated by VISEN, manufactured by WuXi Biologics, and equipped by Tofflon, the project was completed in just 10 months, demonstrating strong industry chain collaboration. Designed for VISEN's first commercial product, Weizhengao®, the line integrates liquid filling and lyophilization molding to optimize drug formulation, packaging, and manufacturing. By overcoming patent barriers related to dual-chamber cartridge pens, VISEN has extended innovation beyond drug development to manufacturing and patient experience. The technology enables room-temperature storage and convenient home injection, highlighting the industry's shift toward addressing the entire drug lifecycle, including storage, transportation, and administration, as a new source of competitive advantage.

Medical imaging data's value is limited by high heterogeneity. To break these barriers, medical AI companies are building multimodal data foundations to open a second growth curve. Focused on pre-acquisition and pre-archiving processing, these foundations convert scattered images into reusable data assets via quality optimization and standardized organization, extending AI value from assisted diagnosis to data generation and continuous use. Rimag, Diagens, Tempus, and Subtle Medical are moving in. Subtle Medical centers on the data source, integrating acquisition optimization, enhancement, and quality control to build a multimodal imaging data foundation linking devices and data centers. Cross-modal combinations enable scan optimization, automated quality control, and upstream standardization, pursuing "First Time Right" so the first scan delivers high-quality data, unlocking imaging data's long-term value.

Physical AI is attracting capital in AI-driven drug discovery. Transfyr, founded in August 2026, raised $25 million in seed funding; Shuye Technology completed a Pre-A round in September to develop self-driving laboratories; Jindu Life Sciences raised nearly RMB 100 million in Series A funding in June; and Medra raised $52 million in Series A funding in late 2025, bringing total funding to $63 million. These startups integrate real-world perception, equipment control, and automated decision-making to develop physical AI scientists and transform life science research. Despite ongoing debate over the definition of Physical AI, investors are backing large-scale early-stage projects, accelerating the integration of AI for Science (AI4S) with physical experiments to overcome traditional limitations in AI-driven drug discovery. No specific investors or financial advisors were disclosed.

Hong Kong's healthcare IPO market weakened sharply in 2026 as listing premiums faded and investor sentiment cooled. In Q3, only two healthcare companies went public, both suffering first-day losses. Highly anticipated listings such as MEDCAPTAIN and Beijing TRT Healthcare also saw steep post-listing declines, with some new listings falling over 60%. The downturn reflects tighter primary-market risk appetite, weaker secondary-market confidence, and reduced tolerance for valuations based on early-stage narratives. IPO activity has consequently slowed, with more companies delaying or abandoning plans. A key factor is the crowded approval pipeline: 87 companies remained in the queue as of September 21, prolonging review cycles and discouraging new applications. The market is entering a phase of more rational restructuring.

On September 29, 2026, Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) announced plans to sell its entire stake in ZIL, an overseas asset held for a decade, to Primavera Capital at an enterprise value of $397 million. The deal is expected to generate approximately RMB 1.336 billion in profit. Following the transfer of Xinte Dong'an Pharmacy, it marks another step in SPH's asset optimization and focus on its core pharmaceutical business. SPH acquired Australian company Vitaco in 2016 to integrate overseas brands with Chinese distribution channels, but expected synergies failed to materialize amid regulatory and cross-border policy changes. As Vitaco shifted toward sports nutrition, its relevance to SPH's core business weakened. The exit concludes SPH's decade-long overseas investment and reflects the broader shift among Chinese pharmaceutical SOEs toward value-focused operations and core capabilities.

On September 18, 2026, the NMPA approved Xinhuanghe Pharma's Budesonide and Formoterol Fumarate Powder for Inhalation (II) for marketing. As China's first approved generic of the product, the approval breaks a foreign monopoly of more than two decades and marks a domestic drugmaker's breakthrough at the "Everest" of dry powder inhalation. Xinhuanghe Pharma's predecessor traces back to Jiufu Pharmaceutical, founded in 1923, which was later folded into Shanghai Pharmaceuticals (SPH) and acquired and renamed by Chenpon in 2014. Amid an industry transition, Chairman Peng Zhaohua chose dry powder inhalation — a technically demanding drug-device combination — over low-cost generics and the hot biologics track. After prolonged investment and R&D breakthroughs across API, formulation, and device, the company has revived a veteran drugmaker and brought patients a high-value domestic alternative.

The medical device industry saw a sharp paradigm shift in 2026: 17 listed device makers unveiled a collective "subtraction" strategy in their half-year reports, reshaping their customer bases. The trend spans IVD, imaging, and consumables, marking a turn from blind scale-chasing to precise quality-chasing. Some shed low-value customers outright — HONSUN, DIAN Diagnostics and others shut inefficient outlets, scaled back low-margin distributor business, and cut loss-making projects, abandoning traditional distribution business with long payment cycles and heavy capital use. Others tactfully refocused on top-tier resources, with Mindray and United Imaging deepening key-account ties and steering resources to high-value-added business. Small distributors and grassroots hospitals are the main casualties, as centralized procurement squeezes terminal margins. This is no short-term winter strategy but a collective pivot to "picking customers" in pursuit of high-quality, sustainable growth.

South Korea’s “cadaver skin injection” Re2O, derived from donated human skin tissue, has sparked ethical and safety concerns in China, bringing extracellular matrix (ECM) into focus. After decellularization, ECM retains biological activity and is widely used in tissue repair. Related medical devices are approved in China, but facial wrinkle reduction is prohibited. Identified as an aging biomarker in 2025, ECM is gaining new applications in medical aesthetics amid advances in microparticulate technology. China’s ECM industry is growing rapidly, with firms such as Shengzhi Runhe and Medgen Life Sciences raising multiple financing rounds and expanding from R&D to mass production. Major medical aesthetics and pharmaceutical companies are also investing in the field, driving ECM toward commercialization.

Viatris Inc. has announced a $1.65 billion cash acquisition of Pacira BioSciences to expand its non-opioid pain management portfolio with established products like EXPAREL and ZILRETTA. In global regulatory developments, China's Jiangsu Hengrui Pharmaceuticals reported that the European Medicines Agency (EMA) has accepted its marketing authorization application for fluzoparib, a PARP inhibitor for metastatic castration-resistant prostate cancer, highlighting its growing ambitions in European markets.

In the first three quarters of 2026, Medtronic invested approximately $2.7 billion in intensive M&A activities. This included leading a $100 million Series D financing round for China-based Pulnovo Medical. Additionally, Medtronic made strategic investments of approximately $700 million in China's Cornerstone Robotics and Israel's Pi-Cardia; acquired three companies, including CathWorks and Scientia Vascular; and invested in Beluga Medical and CARDIOACC. Although the specific financial advisors were not explicitly mentioned in the text, PwC provided relevant data support. Leveraging its strong cash flow, Medtronic aims to address gaps in cardiology and neuroscience through strategic acquisitions, rapidly acquiring high-growth, near-commercialization innovative technologies to synergize with existing businesses and drive growth.

In late September, two global oncology BD deals worth about $2 billion each highlighted the value of Chinese innovative drugs. MSD is acquiring SciBrunch's preclinical oral KRAS G12D inhibitor SPR2015 for up to $2.13 billion to strengthen its solid tumor pipeline. AstraZeneca is investing $2 billion in Summit Therapeutics to advance combination therapies involving Akeso's ivonescimab and CLDN18.2 ADC, while expanding collaboration on multiple ADCs. Despite similar deal sizes and Chinese origins, the transactions reflect different strategies: MSD is using a preclinical small molecule to fill pipeline gaps, while AstraZeneca is leveraging a mature bispecific antibody to explore combination therapies. The deals highlight diverse asset stages, deal structures, and strategic approaches in global oncology BD, as well as the growing global value of Chinese biopharmaceutical innovation.

On September 28, 2026, Shanghai SciBrunch and MSD announced a global exclusive licensing agreement for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor. Under the agreement, SciBrunch grants MSD exclusive worldwide rights to develop, manufacture, and commercialize SPR2015. The deal includes a $400 million upfront payment and milestone payments, with a potential total value of up to $2.13 billion. SPR2015 is a potent and selective molecular glue inhibitor targeting KRAS G12D, the most common KRAS mutation in human tumors. Preclinical studies showed significant antitumor activity across multiple models while maintaining favorable selectivity for wild-type KRAS. The collaboration validates SciBrunch’s R&D capabilities in RAS-targeted therapies and strengthens MSD’s precision medicine pipeline, with potential applications in pancreatic, colorectal, and lung cancers.

Dr. Friedemann Janus, Senior Vice President of Bayer's Pharmaceuticals Division, said China's innovative drugs are embedding deeply into the global system, with about a third of drugs in development originating from China. Multinational pharma's China strategy has shifted from license-in of mature pipeline assets to early engagement with biotech teams to grasp their innovation logic. Bayer, which sees China as a key source of high-quality innovation, has built a network linking startups with global capital and R&D experts via Co.Lab sites in Shanghai and Beijing, a venture capital alliance, and global roadshows during 2024–2025. Janus believes China's pharma industry has moved past "Me-too" and "Fast-Follow" toward "Best-in-Class." The core issue now is how multinational pharma can embed even earlier in China's innovation ecosystem and drive local innovation into global R&D, business development, and commercialization — a fundamental elevation of China's global pharma position.

China’s Center for Drug Evaluation (CDE) has nominated two MASH drug candidates for breakthrough therapy designation: Zhongsheng Pharmaceutical’s ZSP1601 tablets and GSK’s injectable Efimosfermin alfa. ZSP1601, a first-in-class pan-phosphodiesterase (PDE) inhibitor, has entered Phase III trials after showing significant pathological improvement in Phase IIb. At 48 weeks, response rates were 64.9% (100 mg) and 57.6% (50 mg), versus 32.5% for placebo. The drug demonstrated anti-fibrotic effects, reduced liver fat, and improved liver enzymes, with a favorable safety profile. Efimosfermin alfa, a long-acting FGF21 analog administered monthly by subcutaneous injection, is designed to reduce liver fat, improve inflammation, and reverse fibrosis. GSK acquired rights to the drug for up to USD 2 billion and has registered the Phase III ZENITH-2 trial in China following positive Phase II results showing significant histological response in patients with F2/F3 MASH.

On September 22, Suzhou BoomRay announced an exclusive global licensing agreement with Novartis for one of its preclinical radioligand therapy (RLT) assets. BoomRay is eligible to receive up to USD 900 million (approximately RMB 6 billion), including upfront and milestone payments, plus sales royalties. This marks Novartis’s second licensing of an early-stage RLT asset from China this year, following its January acquisition of assets from Hunan PepLib. Despite strong RLT sales, including over USD 1.9 billion in 2025 revenue from Pluvicto, Novartis continues to seek external collaborations to expand its next-generation pipeline targeting novel antigens, ligands, and radionuclides. Founded in 2018, BoomRay has developed an RLT platform covering multiple targets. The deal highlights the global licensing potential of Chinese biotech RLT assets and the growing focus of multinational pharmaceutical companies on early-stage RLT opportunities.

At CCOS 2026, Zhang Jian, vice president of Alcon China, said innovation value must be reflected in responding to real clinical needs and benefiting patients. As China's ophthalmic demands shift from basic "blindness treatment" toward high-definition, personalized, all-scenario visual quality, competition now extends to clinical application capability, professional education, and local innovation. Alcon is redefining its value in China by deepening the integration of global innovation with local clinical practice. It showcased products including the Clareon intraocular lens, the Constellation system, and the ARGOS biometer, and is advancing the rollout of Unity VCS — marking a shift from single devices to systematic clinical solutions, and aiming to complete innovation's "last mile" through continuous clinical validation to genuinely improve patient outcomes.

On September 3, 2026, HUTCHMED announced a worldwide license agreement with GSK for HMPL-A830, its first-in-class KRAS-EGFR dual-targeting antibody-targeted conjugate (ATTC), granting GSK exclusive development and commercialization rights outside Greater China. The drug pairs an anti-EGFR antibody with a KRAS inhibitor payload to dually block signaling pathways, aiming to improve efficacy and tolerability in KRAS-mutant colorectal, pancreatic, and lung cancers. HUTCHMED will receive a USD 110 million upfront payment plus up to USD 1.185 billion in milestones and royalties, retaining Greater China rights; GSK also secured priority negotiation rights for another early-stage ATTC. A global Phase I study led by HUTCHMED is expected in H2 2026, with GSK leading overseas development and commercialization — a milestone for precision oncology addressing unmet need for safe, durable regimens.

Hansoh Pharmaceutical Group has submitted a China marketing application for risvutatug rezetecan (HS-20093), a fully human B7-H3 ADC with a topoisomerase inhibitor payload, for platinum-refractory small cell lung cancer (SCLC). The filing is supported by positive Phase III ARTEMIS-008 results announced in July 2026, which met its primary overall survival endpoint and significantly improved survival versus topotecan, with consistent progression-free survival benefits. Safety remained consistent with prior studies. This is the first positive Phase III result showing a B7-H3 ADC can significantly improve overall survival. In December 2023, Hansoh granted GSK exclusive rights to develop and commercialize the drug outside Greater China, where GSK is conducting Phase III trials. As SCLC accounts for about 15% of lung cancers and has limited second-line options, HS-20093 could address a significant unmet medical need.